Enveric Biosciences Reports Q3 2025 Financial Results with $3.39 Million Net Loss

Enveric Biosciences, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $3.39 million, or $10.81 per share, compared to a net loss of $2.08 million, or $43.10 per share, in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $6.58 million, slightly higher than the $6.42 million loss reported for the same period in 2024. The total operating expenses for the third quarter decreased to $1.87 million from $2.08 million year-over-year, primarily due to reduced research and development costs, which fell by approximately 50% to $402,417.

The company’s financial position showed significant improvement, with total assets increasing to $4.36 million as of September 30, 2025, up from $3.08 million at the end of 2024. Cash reserves also rose to $3.76 million, compared to $2.24 million at the end of the previous fiscal year. This increase in cash was bolstered by net cash provided from financing activities amounting to $7.89 million for the nine months ended September 30, 2025, which included proceeds from a public offering and the exercise of warrants.

Strategically, Enveric has made notable advancements, including the introduction of the EVM401 Series, aimed at expanding its pipeline of non-hallucinogenic molecules targeting addiction and neuropsychiatric disorders. The company also completed a reverse stock split on October 23, 2025, to comply with Nasdaq listing requirements, which has since resulted in a stock price that meets the minimum bid price requirement. Additionally, Enveric entered into an inducement warrant transaction, generating approximately $2.22 million from the exercise of existing warrants at a reduced price.

Operationally, the company has focused on advancing its lead candidate, EB-003, which is designed to engage specific serotonin receptors to provide fast-acting antidepressant effects. The company plans to initiate formal preclinical development studies for EB-003, with the goal of filing for Investigational New Drug (IND) status. However, Enveric's management has expressed concerns regarding its ability to continue as a going concern, citing an accumulated deficit of $112.65 million and ongoing losses. The company is exploring options for additional financing to support its operations and development activities moving forward.